Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ...
Xenon Pharmaceuticals Inc (NASDAQ:XENE), a clinical-stage biopharmaceutical company, focuses on developing therapeutics to improve the lives of patients with neurological disorders. Its pipeline includes a range of neurology-focused therapies.
According to a recent SEC filing, Sherrington Robin, the Executive Vice President of Strategy & Innovation at Xenon Pharmaceuticals Inc (NASDAQ:XENE), sold 7,137 shares of the company on March 7, 2024. The transaction was executed at an average price of $46.28 per share, resulting in a total value of $330,318.36.
Over the past year, the insider has sold a total of 7,137 shares of Xenon Pharmaceuticals Inc (NASDAQ:XENE) and has not made any purchases of the stock.
The insider transaction history for Xenon Pharmaceuticals Inc (NASDAQ:XENE) indicates a pattern of insider sales over the past year, with a total of 8 insider sells and no insider buys recorded during the same timeframe.
On the valuation front, Xenon Pharmaceuticals Inc (NASDAQ:XENE) shares were trading at $46.28 on the day of the insider's recent sale, giving the company a market capitalization of $3.486 billion.
The stock's price-to-GF-Value ratio stands at 356, with a GF Value of $0.13, indicating that Xenon Pharmaceuticals Inc (NASDAQ:XENE) is significantly overvalued according to GuruFocus's valuation model.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
